Bicocca Open Archive

Logo unimib boa
RIZZARI, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.973
EU - Europa 2.634
AS - Asia 1.295
SA - Sud America 27
OC - Oceania 7
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.948
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.871
SG - Singapore 518
IE - Irlanda 479
IT - Italia 463
SE - Svezia 458
RU - Federazione Russa 361
CN - Cina 358
DE - Germania 291
HK - Hong Kong 267
UA - Ucraina 183
GB - Regno Unito 105
CA - Canada 78
AT - Austria 65
FI - Finlandia 63
FR - Francia 53
ID - Indonesia 39
VN - Vietnam 37
NL - Olanda 24
IN - India 23
BR - Brasile 22
TR - Turchia 21
DK - Danimarca 19
BE - Belgio 14
HN - Honduras 11
CZ - Repubblica Ceca 10
BZ - Belize 8
ES - Italia 8
PL - Polonia 7
AU - Australia 6
BG - Bulgaria 5
CH - Svizzera 5
GR - Grecia 5
IR - Iran 5
BD - Bangladesh 4
EU - Europa 4
JP - Giappone 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
EG - Egitto 3
PE - Perù 3
RS - Serbia 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
MX - Messico 2
NO - Norvegia 2
NP - Nepal 2
RO - Romania 2
ZA - Sudafrica 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
IL - Israele 1
IQ - Iraq 1
KH - Cambogia 1
KR - Corea 1
LV - Lettonia 1
MA - Marocco 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
PS - Palestinian Territory 1
PY - Paraguay 1
TW - Taiwan 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.948
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.254
Fairfield 484
Woodbridge 477
Dublin 452
Singapore 450
Chandler 387
Ashburn 288
Houston 279
Hong Kong 262
Wilmington 259
Frankfurt am Main 215
New York 205
Jacksonville 191
Cambridge 183
Seattle 177
Princeton 176
Santa Clara 169
Milan 118
Dearborn 110
Lawrence 88
Altamura 75
Vienna 58
San Diego 53
Beijing 51
Nanjing 48
Shanghai 46
Jakarta 39
Lachine 31
Boardman 29
Buffalo 28
Helsinki 28
Guangzhou 24
London 24
Toronto 24
Andover 22
Rome 20
Los Angeles 19
Council Bluffs 18
Lissone 18
Falls Church 17
Nuremberg 16
Shenyang 14
Changsha 13
Hebei 13
Norwalk 13
Ottawa 13
Brussels 12
Chicago 12
Hangzhou 11
Huizen 11
Jinan 11
Redmond 11
Tegucigalpa 11
Jiaxing 10
Moscow 10
Munich 10
Nanchang 10
Casper 9
Kocaeli 9
Belize City 8
Mountain View 8
Turin 8
Washington 8
Zhengzhou 8
Monza 7
Paris 7
Perugia 7
San Mateo 7
Tianjin 7
Bologna 6
Dong Ket 6
Leawood 6
Olomouc 6
Florence 5
Grafing 5
Athens 4
Clifton 4
Hefei 4
Kardzhali 4
Lisbon 4
Naples 4
Warsaw 4
Adelaide 3
Bangkok 3
Brno 3
Cairo 3
Catania 3
Chengdu 3
Como 3
Edmonton 3
Fuzhou 3
Gaithersburg 3
Gap 3
Kilburn 3
Kunming 3
Lima 3
Ningbo 3
Philadelphia 3
Pune 3
Ravenna 3
Totale 7.306
Salva come PNG Salva come JPEG
Nome #
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 322
Acute myeloid leukaemia niche regulates response to L-asparaginase 321
ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells 266
Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000) 245
Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy 242
A novel EP300 mutation associated with Rubinstein-Taybi syndrome type 2 presenting as combined immunodeficiency 228
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study 226
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 196
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations 195
Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati 187
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study 179
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica 176
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 170
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 170
Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma 169
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica 168
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 162
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 161
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 161
Outcome of very late relapse in children with acute lymphoblastic leukemia 156
Prognostic value of nephromegaly at diagnosis of childhood acute lymphoblastic leukemia 156
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 156
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 155
Screening for Coagulopathy and Identification of Children With Acute Lymphoblastic Leukemia at a Higher Risk of Symptomatic Venous Thrombosis: An AIEOP Experience 154
FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia 150
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy 147
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment 146
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 143
Hermansky-Pudlak syndrome type II and lethal hemophagocytic lymphohistiocytosis: Case description and review of the literature 143
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 137
Williams syndrome and mature B-Leukemia: A random association? 135
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995 133
MTHFR 677C-->T mutation and neural-tube defects 128
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia 128
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica 126
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups 124
Are genotypes of glutathione S-transferase superfamily a risk factor for childhood acute lymphoblastic leukemia? Results of an Italian case-control study 122
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study 122
Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study 120
Role of DNA index in childhood acute lymphoblastic leukemia treated with BFM based therapy: Long term results of the AIEOP-ALL 95 119
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 118
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia 113
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia 112
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study 111
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia 110
Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child 110
Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia 109
Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies 106
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study 104
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II 100
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia 96
Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP) 96
Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol 93
A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1 89
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL 87
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort 72
Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias 67
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD) 66
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia 66
Legionellosis in paediatrics [Legionellosi in pediatria] 57
Nationwide central diagnosis review for childhood solid tumors: From concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project 56
A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia 54
ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment 49
Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children with Influenza 49
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia 48
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial 48
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol 46
Biological therapies in monogenic autoinflammatory diseases: Long-term efficacy and safety 44
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction 44
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data 43
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol 42
Road Traffic Pollution and Childhood Leukemia: A Nationwide Case-control Study in Italy 42
Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia 42
Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO 41
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia 41
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring 41
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium 41
Therapeutic drug monitoring of asparaginase activity - Method comparison of MAAT and AHA test used in the international AIEOP-BFM ALL 2009 trial 39
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation 38
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? 38
NUP214–ABL1 fusion in childhood T-ALL 38
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL 37
A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety 37
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study 36
Still trying to pick the best asparaginase preparation 35
Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study 35
Collaborative efforts driving progress in pediatric acute myeloid leukemia 35
Human Fibrinogen Concentrate and Fresh Frozen Plasma in the Management of Severe Acquired Hypofibrinogenemia in Children with Acute Lymphoblastic Leukemia: Results of a Retrospective Survey 35
Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product 35
Recommendations by the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) Working Group on preparedness of clinical trials about paediatric medicines process 34
Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25-year Italian experience 34
Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): Summary of an expert panel discussion 33
CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript 33
Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial 32
Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement 32
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study 30
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 30
Emapalumab in children with primary hemophagocytic lymphohistiocytosis 30
Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing 30
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial 29
Totale 10.282
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.380
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.380
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020440 0 0 0 0 0 0 0 98 127 89 96 30
2020/20211.539 76 51 130 141 147 243 136 150 98 163 97 107
2021/20221.311 85 99 105 164 141 135 53 67 106 81 71 204
2022/20231.712 247 528 95 149 112 278 18 82 117 16 44 26
2023/20241.355 83 33 58 69 168 353 275 32 117 22 18 127
2024/20251.707 182 509 210 183 307 94 171 51 0 0 0 0
Totale 10.498